We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PXS-5505

News List

FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer AmericanPharmaceuticalReview
November 10, 2021
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that an Investigational New Drug application (IND) for a trial of PXS-5505 in hepatocellular carcinoma (HCC)...
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model prnasia
August 05, 2021
Clinical stage drug development company Pharmaxis Ltd today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) ...